RxDoctor Payments Data

Blake Williams

Nurse Practitioner · Des Moines, IANPI 1245624626

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (47.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 79.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $5,435 and has fallen 91.5% since, to $460 in 2025. Among nurse practitioner clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,399in general payments, 2019–2025

Across 79 payments — averaging $80.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$5K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$547
  • Madrigal Pharmaceuticals$358
  • AbbVie$163
  • Ipsen Biopharmaceuticals, Inc$146
  • Intercept Pharmaceuticals, Inc.$58
  • plus $71 from 3 others

What the payments were for

  • Speaking & faculty fees$3,02047%
  • Travel & lodging$1,44623%
  • Food & beverage$1,93330%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,399 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in Iowa.

See all nurse practitioner providers in Iowa

Medicare billing

Part B allowed, 2024
$60,806
Medicare patients
322
Services billed
796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin141$460,696
OcalivaObeticholic Acid12$113,612
VemlidyTenofovir Alafenamide43$68,426
Ursodiol165$21,191
Lactulose124$4,481
Azathioprine93$2,286
Mycophenolate Mofetil24$2,208
Spironolactone179$1,860
Nadolol47$1,599
Midodrine Hcl33$1,585
Hydroxyzine Hcl55$1,343
Entecavir26$965
Propranolol Hcl54$886
CholestyramineCholestyramine (With Sugar)14$794
Furosemide203$588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$547$460,696141 claims
Intercept Pharmaceuticals, Inc.Ocaliva$58$113,61212 claims
GileadVemlidy$5,054$68,42643 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in Iowa.

Other nurse practitioner in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →